scispace - formally typeset
E

Elham Sajjadi

Researcher at European Institute of Oncology

Publications -  57
Citations -  538

Elham Sajjadi is an academic researcher from European Institute of Oncology. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 9, co-authored 28 publications receiving 163 citations. Previous affiliations of Elham Sajjadi include Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico & Shahid Beheshti University of Medical Sciences and Health Services.

Papers
More filters
Journal ArticleDOI

The evolving landscape of Anatomic Pathology.

TL;DR: Anatomic pathology has changed dramatically in recent years as mentioned in this paper and pathologists have had to acquire additional knowledge to bridge the gap between clinicians and molecular biologists, which is particularly important as cases are now collegially discussed in molecular tumor boards (MTBs).
Journal ArticleDOI

Low-risk triple-negative breast cancers: clinico-pathological and molecular features.

TL;DR: In this paper , the authors provided a portrait of the clinicopathological and molecular features of low-risk triple negative breast cancer, with a focus on the diagnostic challenges along with the most important biological characteristics underpinning their favorable clinical course.
Journal ArticleDOI

Increased expression ratio of matrix metalloproteinase-9 (MMP9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) RNA levels in Iranian multiple sclerosis patients.

TL;DR: Although there was no significant decrease in TIMP-1 expression level, the MMP-9/TIMp-1 RNA ratio in RRMS was significantly higher than normal subjects, and further studies are recommended to compare M MP-9-to-TIMP-2RNA ratio in patients before and after taking IFN-beta in order to find out if it can function as a proper marker of the bio efficacy of IFn-beta treatment of MS.
Journal ArticleDOI

Lymphedema Rehabilitation Using Self-Adaptive Inelastic Compression in Breast Cancer: A Proof-of-Principle Study

TL;DR: It is suggested that IC could be considered as a safe, well-tolerated, and effective tool in the rehabilitative management of BCRL patients.
Journal ArticleDOI

Mismatch Repair Status Characterization in Oncologic Pathology: Taking Stock of the Real-World Possibilities

TL;DR: The indications and challenges in MMR status assessment for molecular pathologists are highlighted, focusing on the possible strategies to overcome analytical and pre-analytical issues.